Skip to main content

Articles By Jack Cush, MD

podcast logo

RheumNow Podcast – Back Talk: Questions from Listeners (10.23.20)

By Jack Cush, MD
23 October 2020

Dr. Jack Cush reviews the news, journal reports, survey results and "Back Talk" questions from Rheums.

Read Article
burnout work overworked

High Burnout Rates Among Rheumatologists

By Jack Cush, MD
22 October 2020

Bergman and colleagues have studied a large cohort of US rheumatologists and found that nearly half meet at least one criterion defining "burnout" among physicians.

Read Article
COVID.virus_.corona_1.jpg

Remdesivir FDA Approved for Hospitalized COVID-19

By Jack Cush, MD
22 October 2020

The FDA has approved Gilead Sciences Inc’s antiviral drug remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease in the United States.

Read Article
Covid lung pneumonia corona

Clinical Trial Boom or Bust in Severe COVID-19

By Jack Cush, MD
20 October 2020

A number of recently published clinical trials are further defining the efficacy and outcomes of tocilizumab or remdesivir in treating SARs-CoV-2 infection. Remdesivir

Read Article
depression oh no HA

Biologic Use for Arthritis Linked With Depression and Anxiety

By Jack Cush, MD
20 October 2020

In a recent study of patients with inflammatory rheumatic diseases, the initiation of a biologic treatment or switching to another biologic was associated with an increased likelihood of the use of antidepressants and anxiolytics, reported Petros P. Sfikakis, MD, of the National and Kapodistrian University of Athens, and colleagues in RMD Open: Rheumatic & Musculoskeletal Diseases.

Read Article
shoulder.exam__0.jpg

Outpatient Visits Return to Pre-COVID Rates

By Jack Cush, MD
19 October 2020

The COVID-19 pandemic dramatically impacted outpatient care - numbers, scope, quality, etc, but a recent study suggests that while COVID has changed the scope of care, the numbers of outpatient visits have risen to near pre-pandemic numbers.

Read Article
choices_0.jpg

TNF Inhibitors or non-TNF Biologics - First Best Choice?

By Jack Cush, MD
18 October 2020

Prospective observational findings from the CORRONA registry of rheumatoid arthritis (RA) patients compared clinical outcomes between initial aggressive therapy using either a tumour necrosis factor inhibitor (TNFi) or a non-TNFi (biological disease-modifying antirheumatic drugs (bDMARDs) and tar

Read Article
podcast logo

RheumNow Podcast – Good Time Charlie…. (10.16.20)

By Jack Cush, MD
15 October 2020

Dr. Jack Cush sings the news and journal reports from the past week on RheumNow.com.

Read Article
UPA ABA box

Abatacept vs. Upadacitinib in Biologic Refractory Rheumatoid Arthritis

By Jack Cush, MD
15 October 2020

NEJM reports the results of the SELECT-Choice trial, a head to head study of upadacitinib (UPA) and abatacept (ABA) in biologic refractory rheumatoid arthritis (RA); 12 weeks results showed UPA was significantly more clinically effective than ABA using a DAS28-CRP remission, but ABA had fewer safety signals and serious adverse events.

Read Article
URI.infection.COrona_0.jpg

COVID Transmission from Young to Old

By Jack Cush, MD
13 October 2020

The CDC has analyzed temporal trends in percent positivity by age group in COVID-19 hotspot counties before and after their identification as hotspots.

Read Article
×